Annals of Oncology 2:745-749, 1991
© 1991 European Society for Medical Oncology
research-article |
Original article: Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols
From the Kinderklinik der Medizinischen Hochschule, Hannover, FRC; the Department of Pediatric Oncology and the Division of Biostatistics, Dana-Farber Cancer Institute; the Division of Hematology/Oncology of The Children's Hospital; the Department of Biostatistics, Harvard School of Public Health, and the Department of Pediatrics, Harvard Medical School, Boston, U.S.A.
Correspondence to: Charlotte M. Niemeyer, M.D. University Hospital of Freiburg Children’s Hospital Mathildenstrasse 1 7800 Freiburg i. Br. Federal Republic of Germany
We analyzed two of the most successful trials for childhood acute lymphoblastic leukemia, from the Berlin-Frankfurt-Munster group (BFM) and the Dana-Farber Cancer Institute (DFCI), to determine their similarities and differences and suggest ways to improve future treatments. Protocol ALL-BFM 81 (n = 611) was conducted between 1981–1983 in 37 centers in West Germany and Austria; Protocol DFCI 81–01 (n = 286) was conducted between 1981–1985 in seven centers within the United States. The BFM study used a risk score, based on peripheral lymphoblast count, liver size, and spleen size at the time of diagnosis to assign patients into one of the three treatment arms. The DFCI study classified patients into two groups: standard risk patients (age 2–9 years, with white blood count <20, 000/mm3, and with no T-cell markers, mediastinal mass, nor central nervous system disease), and high risk patients (all others). Both studies involved intensive chemotherapy, although treatment strategies, cumulative drug doses and cranial radiation protocols differed. Study populations in the two trials were comparable with respect to age, sex, white blood count and proportion of patients with T-cell markers at the time of diagnosis. Using DFCI risk group criteria, 37% of BFM and 38% of DFCI patients were classified as standard risk. Median follow-up times were 6.8 years and 6.1 years, respectively. Six-year event-free survival percentages (± standard error) were nearly identical: BFM 69%(±2%) and DFCI 70%(±3%) overall; BFM 79%(±3%) and DFCI 80%(±5%) for standard risk patients; and BFM 63%(±2%) and DFCI 63%(±4%) for high risk patients. In both studies, outcomes for boys and girls were similar. The BFM study had a higher incidence of testicular relapse (p =0.004) and CNS relapse (p =0.004; especially among the 177 non-irradiated patients), than the DFCI study, but a lower incidence of death in remission (p =0.20). While none of the five infants less than one year old in the DFCI protocol were successfully treated, seven of 10 infants in the BFM trial remained disease-free (p = 0.0004). Because the patterns of relapse differed, we recommend the integration of major components of each program into a single, new protocol in order to improve outcome.
acute leukemia, lymphoblastic, childhood, treatment, comparative analysis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Clarke, P. Gaynon, I. Hann, G. Harrison, G. Masera, R. Peto, and S. Richards CNS-Directed Therapy for Childhood Acute Lymphoblastic Leukemia: Childhood ALL Collaborative Group Overview of 43 Randomized Trials J. Clin. Oncol., May 1, 2003; 21(9): 1798 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rizzari, M.G. Valsecchi, M. Arico, V. Conter, A. Testi, E. Barisone, F. Casale, L. Lo Nigro, R. Rondelli, G. Basso, et al. Effect of Protracted High-Dose L-Asparaginase Given as a Second Exposure in a Berlin-Frankfurt-Munster-Based Treatment: Results of the Randomized 9102 Intermediate-Risk Childhood Acute Lymphoblastic Leukemia Study--A Report From the Associazione Italiana Ematologia Oncologia Pediatrica J. Clin. Oncol., March 1, 2001; 19(5): 1297 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Mattano Jr, H. N. Sather, M. E. Trigg, and J. B. Nachman Osteonecrosis as a Complication of Treating Acute Lymphoblastic Leukemia in Children: A Report From the Children's Cancer Group J. Clin. Oncol., September 18, 2000; 18(18): 3262 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. R.-v. Woerden, R. Pieters, A. H. Loonen, I. Hubeek, E. van Drunen, H. B. Beverloo, R. M. Slater, J. Harbott, J. Seyfarth, E. R. van Wering, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia Blood, August 1, 2000; 96(3): 1094 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Pui, J. M. Boyett, M. V. Relling, P. L. Harrison, G. K. Rivera, F. G. Behm, J. T. Sandlund, R. C. Ribeiro, J. E. Rubnitz, A. Gajjar, et al. Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia J. Clin. Oncol., March 1, 1999; 17(3): 818 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Loh, L. B. Silverman, M. L. Young, D. Neuberg, T. R. Golub, S. E. Sallan, and D. G. Gilliland Incidence of TEL/AML1 Fusion in Children With Relapsed Acute Lymphoblastic Leukemia Blood, December 15, 1998; 92(12): 4792 - 4797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Harbott, S. Viehmann, A. Borkhardt, G. Henze, and F. Lampert Incidence of TEL/AML1 Fusion Gene Analyzed Consecutively in Children With Acute Lymphoblastic Leukemia in Relapse Blood, December 15, 1997; 90(12): 4933 - 4937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Smith, J. Abrams, E. L. Trimble, and R. S. Ungerleider Dose Intensity of Chemotherapy for Childhood Cancers Oncologist, October 1, 1996; 1(5): 293 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Pratt Pediatric Clinical Trials Oncologist, June 1, 1996; 1(3): 169 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Rivera, D. Pinkel, J. V. Simone, M. L. Hancock, and W. M. Crist Treatment of Acute Lymphoblastic Leukemia -- 30 Years' Experience at St. Jude Children's Research Hospital N. Engl. J. Med., October 28, 1993; 329(18): 1289 - 1295. [Abstract] [Full Text]
|
|